
    
      It is a 2-part study in hospitalized COVID-19 patients.

        -  Part 1 is to evaluate safety, tolerability, PK and markers of clinical activity of
           escalating doses of PF-07304814 given as 24-hour IV infusion.

           2 planned and 3 optional cohorts with 8 participants each are planned.

        -  Part 2 is to evaluate safety, tolerability, PK and markers of clinical activity of
           escalating doses of PF- 07304814 given as 120-hour infusion.

           2 planned and 2 optional cohorts with 8 participants each are planned
    
  